March 28, 2026 01:17 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Feeling blessed’: PM Modi attends Surya Tilak ceremony at Ayodhya Ram Temple virtually | ‘No lockdown’: Union Minister Hardeep Singh Puri dismisses rumours, assures preparedness amid West Asia tensions | Middle East crisis: Govt cuts excise duty by Rs 10 on petrol and diesel, giving big relief amid global oil shock | ‘Big boost for NCR connectivity’: PM Modi to inaugurate Noida International Airport Phase 1 tomorrow | HDFC chairman Atanu Chakraborty resigned over power struggle with CEO Sashidhar Jagdishan: Report | PM Modi to chair meeting with CMs tomorrow amid West Asia conflict | ‘I said, no thanks’: Trump claims Iran offered him Supreme Leader role | Iran allows India, four other ‘friendly nations’ access to Strait of Hormuz amid West Asia conflict | 13 killed as bus, lorry collide and catch fire in Andhra Pradesh | Mamata unveils TMC candidate list for Bengal polls; to face Suvendu in Bhabanipur
Serum Institute

CCI approves merger of Serum Institute subsidiaries Biocon Biologics and CTPL

| @indiablooms | May 20, 2022, at 12:09 am

New Delhi: The Competition Commission of India (CCI) has approved the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15 percent equity shareholding of Biocon Biologics by Serum Institute Life Sciences.

The Proposed Combination involves a merger by absorption of Covidshield Technologies Private Limited (CTPL), a wholly-owned subsidiary of the Serum Institute Life Sciences Private Limited (Acquirer) into the Biocon Biologics Limited (Target) pursuant to a scheme of the merger in consideration of which the Acquirer will acquire approximately 15 percent equity shareholding on a fully diluted basis in the Target, CCI said in a statement on Thursday.

The acquirer is a subsidiary of Serum Institute of India Private Limited and was established as a company for further development and commercialization of vaccines and therapies against COVID-19, the anti-trust watchdog stated.

It also had plans to further develop vaccines against other infectious diseases.

At present, the acquirer is in the process of setting up its own manufacturing facility.

CTPL is a wholly-owned subsidiary of the acquirer, which shall be merged into the Target pursuant to the Proposed Transaction.

It was incorporated to undertake the business of marketing, selling, and distributing vaccines, drugs and other pharmaceutical products.

The Target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases.

The Target also has research and development centres in Bengaluru and Chennai.

It has manufacturing facilities in Bengaluru and Malaysia for monoclonal antibodies, recombinant proteins and insulins.

Detailed order of the CCI will follow.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm